Qelbree is a nonstimulant that is an effective, safe*, and convenient medication for children aged 6 to 17 with attention deficit hyperactivity disorder (ADHD). Important: Keep an eye on your youngster for changes in mood or behavior. Changes in blood pressure and heart rate may be monitored by your child's doctor.

The prescription drug QelbreeTM (viloxazine extended-release capsules) is used to treat ADHD in children aged 6 to 17.


Suicidal thoughts and behaviors may be increased by Qelbree, especially in the first few months of treatment or when the dose is modified. Before starting Qelbree, tell your child's doctor if they have had suicide thoughts or actions (or if there is a family history of suicidal thoughts or actions). During Qelbree treatment, keep an eye on your child's moods, behaviors, thoughts, and feelings. Any new or unexpected changes in these symptoms should be reported right away.

If your child has any of the following conditions, he or she should not take Qelbree:

Take a monoamine oxidase inhibitor (MAOI) for depression or have stopped taking one in the recent 14 days. Alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline should also be avoided by your youngster.

Qelbree has the potential to raise blood pressure and heart rate. These vital signs will be monitored by your child's doctor.

In bipolar disorder patients, Qelbree may produce manic episodes. If your child exhibits any signs of mania, contact their doctor.

Allow your teen to drive or operate heavy machinery only after you have determined how Qelbree will effect them. Qelbree could make your teen sleepy or fatigued.

Sleepiness, hunger, fatigue, nausea, vomiting, difficulty sleeping, and irritability are the most prevalent side effects of Qelbree. These aren't all of Qelbree's possible negative effects.

You can contact the FDA at 1-800-FDA-1088 or go to www.fda.gov/medwatch to report negative side effects.